MARKET

ALT

ALT

Altimmune
NASDAQ
2.675
+0.005
+0.19%
Opening 10:19 10/07 EDT
OPEN
2.640
PREV CLOSE
2.670
HIGH
2.690
LOW
2.630
VOLUME
480.04K
TURNOVER
--
52 WEEK HIGH
6.44
52 WEEK LOW
2.560
MARKET CAP
520.33M
P/E (TTM)
-3.4494
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALT last week (0928-1002)?
Weekly Report · 2d ago
Altimmune Appoints Richard Menziuso as Principal Accounting Officer
TipRanks · 09/29 11:29
Weekly Report: what happened at ALT last week (0921-0925)?
Weekly Report · 09/28 09:03
Altimmune’s Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for Investors
TipRanks · 09/23 16:30
Altimmune Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 09/23 13:22
Altimmune Price Target Cut to $17.00/Share From $18.00 by Evercore ISI Group
Dow Jones · 09/23 13:22
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17
Benzinga · 09/23 13:11
Altimmune price target lowered to $17 from $18 at Evercore ISI
TipRanks · 09/23 12:00
More
About ALT
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Webull offers Altimmune Inc stock information, including NASDAQ: ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.